Filter
325
Text search:
National
Pharmacovigilance
Policy
Featured
35
103
Language
Document type
159
59
43
27
23
7
4
3
Countries
17
15
14
13
12
11
11
9
8
8
7
6
6
6
6
5
5
5
5
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
160
38
9
6
5
5
5
Toolboxes
41
37
26
24
21
17
6
5
3
3
2
2
2
1
1
1
1
1
Towards ending tuberculosis and multidrug-resistant tuberculosis.
ຢາຕ້ານເຊື້ອຈຸລະຊີບ (Antimicrobial medicines) ມີຄວາມສໍາຄັນຫຼາຍຕໍ່ວຽກງານການແພດ, ສາທາລະນະສຸກ, ສຸຂະພາບສັດ ແລະ ການຜະລິດອາຫານ. ເນ
...
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership and continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill a
...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Global UNIDO Project: Strengthening the local production of essential medicines in least developed and developing countries
This annual report gives an overview of WHO lesotho Country office's undertakings and achievements in the context of an extraordinary health emergency. As we walk another mile this year, may we embrace all lessonst leanred in the previous year, learn from what did not work so well and take on new op
...
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s
...
